Nano-X Imaging Ltd. Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd. filed this Form 6-K for July 2023. The filing reports the July 26, 2023 closing of a registered direct offering to a single institutional investor. The transaction involved the sale of 2,142,858 ordinary shares and warrants to purchase up to an additional 2,142,858 ordinary shares.
Transaction and Key Financial Terms
- Combined purchase price: $14.00 per share-and-warrant unit.
- Warrant exercise price: $19.00 per ordinary share.
- Warrants: Immediately exercisable and expiring five years after issuance; exercisable for cash only while an effective registration statement covers the underlying shares.
- Expected net proceeds: Approximately $28.2 million, excluding potential warrant exercise proceeds.
- Placement agent compensation: Cash fee equal to 5.5% of gross offering proceeds, plus reimbursement of certain legal fees.
- No revenue, profit, cash flow, margin, debt, or liquidity metrics for a comparable reporting period are provided in this filing.
Use of Proceeds and Material Changes
Nano-X intends to use the net proceeds for general working capital, further development of the Nanox.ARC, Nanox.CLOUD, and other products, and the manufacture and commercial deployment of the Nanox System. The filing does not provide a prior-period comparison or quantify a change in cash, debt, revenue, or operating results.
Restrictions, Risks, and Other Terms
- The company agreed to a 30-day standstill after closing, generally restricting certain equity issuances and registration filings, subject to specified exceptions. The restriction ends if the ordinary share closing price reaches at least $17.00 per share.
- Warrant exercise is subject to beneficial ownership limitations of 4.99%, or 9.99% if elected by the holder.
- The offering was conducted under the company’s effective Form F-3ASR shelf registration statement, as amended by a post-effective amendment filed July 26, 2023.
- The transaction includes customary representations, warranties, covenants, closing conditions, and indemnification provisions.
- Potential future warrant exercises could provide additional proceeds but would also result in issuance of additional ordinary shares. The filing does not state that any warrants were exercised as of the filing date.
Investor Verification Checklist
- Verify the final allocation and net cash proceeds in subsequent financial statements.
- Assess the potential dilution from the 2,142,858 warrants and any later equity issuances.
- Review the full securities purchase agreement, placement agency agreement, and warrant terms filed as Exhibits 4.1 through 4.3.
- Evaluate whether the proceeds are sufficient to support development and commercial deployment of the Nanox System.
- Confirm the company’s cash balance, liquidity runway, operating losses, and financing needs in its next periodic report.